Page 9 - Diagnostics Division News Today

SOUTH SAN FRANCISCO (dpa-AFX) - Swiss drug major Roche (RHHBY) reported Wednesday that its third-quarter Group sales were 15.97 billion Swiss francs, up from 14.70 billion francs last year. Constant

Investor Update Ad hoc announcement pursuant to Art. 53 LR Basel, 20 October 2021 Roche reports strong growth in the... | October 20, 2021

Basel, 20 October 2021 Group sales up 8%1 at constant exchange rates (CER); 6% in Swiss francsPharmaceuticals Division sales grow 5% in the third quarter and are now in line with the prior year for

Investegate announcements from Avacta Group PLC, Issue of Equity and Total Voting Rights

Autor: Meditsiiniuudised • 30. juuli 2021 RAADIO: keskpäevane trenn on halb mõte Suvekuumas tuleks keskpäevasest treeningust hoiduda, tõdeb Lääne-Tallinna Keskhaigla funktsionaaldiagnostika osakonna juhataja kardioloog Ene Pullisaar reedel 30. juulil Äripäeva Raadio Terviseuudiste saates. Kardioloog Ene Pullisaar Autor: LTKH Seekordne suvi on olnud kuum ja päikseline nagu lõunamaades. Kuidas kuumus mõjub südamele ja mida teha, et organism ikka vastu peaks ja suve nautida lubaks? ...

Investegate announcements from Avacta Group PLC, MHRA Confirms Registration of Lateral Flow Test

    Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that its Annual Report and Accounts for the year ended 31 December 2020 and the Notice of the 2021 Annual General Meeting are now available on the Companys website, www.avacta.com. Copies of the Annual Report and Accounts and the Notice of AGM have been posted to shareholders who ha...

Investegate announcements from Avacta Group PLC, Change of Nominated Adviser

Investegate announcements from Avacta Group PLC, Issue of Equity

Commenting on the Group’s performance in the first quarter, Roche CEO Severin Schwan said: “In 2021, Roche remains strongly committed to the fight against COVID-19. The uptake of our recently introduced diagnostic tests and medicines remains strong, while we continue to see the expected impact from biosimilars on sales of our established medicines. Our broad product pipeline keeps making good progress. I am particularly pleased about the highly encouraging study results of our immun...